ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

In Brief: Sparano Named Vice Chair of ECOG-ACRIN

May 17, 2013

FDA Orders More Changes In ESA Label,

August 8, 2008

Institute of Medicine Elects 70 Members at Annual Meeting

October 25, 2013

ColoPrint Improves Prognosis In Stage II and III Colon Cancer

January 28, 2011

In Brief: Moloney, Manaher, 11 Other NCI Staff Members Retire; Terry Takes Leave From Immunology Jobs

March 7, 1980

FDA Rejects Genentech Bid For Accelerated Approval For T-DM1. NCI Breaks Ground For Satellite Campus At Shady Grove

September 3, 2010